The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
As we have highlighted in past articles, many people with Medicare—and many callers to our national consumer helpline—struggle to afford
On Tuesday, President Trump issued an executive order on prescription drug pricing that supports key drug industry efforts to weaken
This week, Medicare Rights submitted comments in response to the annual Medicare Advantage (MA) and Part D proposed rule for
A comprehensive commentary by the Medicare Rights Center on the Centers for Medicare & Medicaid Services (CMS) proposed rule for Contract Year 2026 (CMS–4208–P). The document outlines feedback and recommendations on changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and related policies. Topics include consumer protections, health equity, benefit transparency, drug affordability, and the integration of AI in healthcare services. This submission emphasizes safeguarding beneficiary access to affordable, equitable, and transparent healthcare.
On January 17, the U.S. Department of Health and Human Services (HHS) announced the 15 Part D drugs that will
A new report from the Department of Health and Human Services Assistant Secretary for Planning and Evaluation (ASPE) projects that
Annual changes to premiums and cost-sharing, as well as the continued rollout of significant Part D reforms included in the
What Is the Low-Income Subsidy (LIS)? The Low-Income Subsidy (LIS), also called Extra Help, is a federally administered assistance program
The Inflation Reduction Act (IRA) made significant improvements to Medicare prescription drug access and affordability, including by restructuring the Part
Key components of the Inflation Reduction Act’s Part D reforms will be fully implemented for plans offered in 2025. These
As we have highlighted in past articles, many people with Medicare—and many callers to our national consumer helpline—struggle to afford
On Tuesday, President Trump issued an executive order on prescription drug pricing that supports key drug industry efforts to weaken
This week, Medicare Rights submitted comments in response to the annual Medicare Advantage (MA) and Part D proposed rule for
A comprehensive commentary by the Medicare Rights Center on the Centers for Medicare & Medicaid Services (CMS) proposed rule for Contract Year 2026 (CMS–4208–P). The document outlines feedback and recommendations on changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and related policies. Topics include consumer protections, health equity, benefit transparency, drug affordability, and the integration of AI in healthcare services. This submission emphasizes safeguarding beneficiary access to affordable, equitable, and transparent healthcare.
On January 17, the U.S. Department of Health and Human Services (HHS) announced the 15 Part D drugs that will
A new report from the Department of Health and Human Services Assistant Secretary for Planning and Evaluation (ASPE) projects that
Annual changes to premiums and cost-sharing, as well as the continued rollout of significant Part D reforms included in the
What Is the Low-Income Subsidy (LIS)? The Low-Income Subsidy (LIS), also called Extra Help, is a federally administered assistance program
The Inflation Reduction Act (IRA) made significant improvements to Medicare prescription drug access and affordability, including by restructuring the Part
Key components of the Inflation Reduction Act’s Part D reforms will be fully implemented for plans offered in 2025. These
